Compare SRPT & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | JLS |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 99.6M |
| IPO Year | 2000 | N/A |
| Metric | SRPT | JLS |
|---|---|---|
| Price | $17.08 | $18.00 |
| Analyst Decision | Hold | |
| Analyst Count | 28 | 0 |
| Target Price | ★ $25.76 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 15.3K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $16.80 |
| 52 Week High | $80.88 | $19.09 |
| Indicator | SRPT | JLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 34.25 |
| Support Level | $17.05 | N/A |
| Resistance Level | $19.55 | $18.89 |
| Average True Range (ATR) | 0.88 | 0.32 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 62.72 | 37.95 |
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.